Who Should Not Get NAD+ Injections? Safety, Eligibility, and Evidence Limits

There is no well-established, evidence-based list of people who should never receive NAD+ injections. The human studies most often cited involve oral NAD-related supplements—not compounded NAD+ injections—so a licensed clinician must review a person’s health history, medications, goals, and proposed formulation before deciding whether treatment is appropriate 1 2 3.

What should I know before considering NAD+ injections?

NAD+ injections are not the same intervention as oral NMN or NR supplements. The central fact is that the supplied human research is on oral supplements, so it cannot show that a compounded injection is safe, effective, or appropriate for a particular person 1 2 3.

NAD+ is an endogenous cellular coenzyme that helps enzymes move electrons during reactions involved in cellular energy metabolism 1 2 3. That basic biology is real, but it does not establish that raising NAD-related compounds through any specific product will improve longevity, prevent disease, or produce a particular health outcome in people.

This distinction matters because formulation and route can change how a substance is used and evaluated. A clinician should consider the actual compounded formulation, rather than assuming findings from a capsule apply to an injection or nasal spray 4 5.

Is there a clear list of people who should not get NAD+ injections?

No universal contraindication list has been established for compounded NAD+ injections. The relevant human trials have not created a clear, injection-specific rulebook for eligibility, and they do not replace an individual medical evaluation 1 2 3.

That does not mean everyone is a candidate. It means clinicians need to make the decision using the person in front of them: their medical history, medications and supplements, allergies, treatment goals, and the exact product being considered. A provider may decide treatment is not appropriate, may need more information, or may recommend a different approach.

Why oral NAD-related supplement studies do not establish injection eligibility

The 2023 Yi trial was a randomized, double-blind, placebo-controlled study of oral NMN in healthy middle-aged adults—not an NAD+ injection trial 1. The 2021 Yoshino trial studied oral NMN in prediabetic women and reported a muscle insulin-sensitivity finding; it did not evaluate compounded NAD+ injections 2.

Likewise, the NADPARK phase I trial studied oral nicotinamide riboside, or NR, in people with Parkinson’s disease. It cannot establish the safety or effectiveness of compounded NAD+ injections for Parkinson’s disease or for any other person or goal 3. These studies also have their own safety monitoring and participant criteria, which cannot simply be transferred to another formulation.

What a clinician needs to determine before prescribing

A clinician generally needs enough information to assess whether the requested treatment fits a patient’s situation. That can include current prescriptions and over-the-counter products, relevant medical history, prior reactions to medicines, pregnancy or breastfeeding status, and what the person hopes treatment will do. This is an eligibility review, not a guarantee of a prescription.

A useful conversation also separates a reasonable goal—such as asking about a NAD-related treatment—from claims the evidence cannot support. Current oral NMN and NR trials do not prove that compounded NAD+ injections improve lifespan, reverse aging, or treat a disease 1 2 3.

What evidence is available on NAD+ and related supplements?

The best available human evidence here is from oral-supplement trials published from 2021 to 2023. These are useful early studies, but they are not clinical trials of compounded NAD+ injections 1 2 3.

Human research on oral nicotinamide mononucleotide (NMN)

Yi and colleagues ran a randomized, multicenter, double-blind, placebo-controlled trial of oral NMN in healthy middle-aged adults 1. Yoshino and colleagues also conducted a randomized trial of oral NMN in prediabetic women and reported increased muscle insulin sensitivity 2.

These are human randomized controlled trials, which are stronger than anecdotes or animal studies. But their findings concern the studied oral NMN products and study populations. They do not establish benefits from NAD+ injections, and individual results from any treatment can vary.

Human research on oral nicotinamide riboside (NR)

Brakedal and colleagues conducted the NADPARK randomized phase I trial of oral NR supplementation in people with Parkinson’s disease 3. A phase I study can provide useful safety and feasibility information for the intervention it tests, but it is not proof that another NAD-related formulation has the same safety profile or clinical effect.

The same balanced reading applies to side effects and risks. Study safety findings for oral NMN or NR cannot be used to predict injection-specific effects, medication interactions, or suitability for a particular person 1 2 3.

What these studies cannot tell us about compounded NAD+ injections

They cannot tell us whether compounded NAD+ injections improve longevity, prevent disease, or are safe for every person. They also cannot establish the best route, dose, frequency, or duration for an individual. Those are important evidence gaps—not details to fill in with social-media protocols or advice from unlicensed sellers.

For a broader evidence review, see our guide to NAD+ shots and what the research shows and our comparison of NAD+ injections versus oral products.

What safety questions should I discuss with a clinician before NAD+ treatment?

The most important safety step is an individual review before treatment begins. A clinician can look at the whole picture—health history, current medicines, other supplements, and the exact formulation—rather than relying on a generic online “safe” or “unsafe” list.

Medical history, medications, and treatment goals

Bring a current medication and supplement list to the evaluation, and explain what you want help with. This gives the clinician a chance to identify questions that need follow-up and to explain whether the available evidence fits the goal. No current oral NMN or NR study establishes compounded NAD+ injection treatment for a specific condition 1 2 3.

Pregnancy, breastfeeding, and other situations with limited evidence

Pregnancy and breastfeeding should be discussed directly with a licensed clinician before seeking a NAD-related treatment. The supplied oral NMN and NR trials do not establish injection eligibility or outcomes for pregnant or breastfeeding people 1 2 3. A provider may need to consider limited evidence and individual circumstances before making a decision.

Why product source and formulation matter

A prescription pathway adds meaningful safeguards: a licensed provider evaluates the request, and a state-licensed pharmacy compounds and dispenses the medication. FDA explains that compounded drugs are not FDA-approved and have not undergone FDA premarket review for safety, effectiveness, or quality 4 5.

That is different from buying a product labeled “NAD+” from an unlicensed research-chemical vendor. Product identity, sterility, quality controls, and clinical accountability are central safety questions for anything intended for injection 5.

How do compounded NAD+ injections differ from FDA-approved medications?

Compounded NAD+ injections are not FDA-approved medications. Compounding is a pharmacy practice governed by federal and state requirements; it is not the same as FDA approval of a finished drug product 4 6.

What compounded medication means

A compounded medication is prepared by a pharmacy for an individual patient based on a prescription. Section 503A of the Federal Food, Drug, and Cosmetic Act sets conditions for traditional pharmacy compounding, while states license and oversee pharmacies 6 7.

Why compounded NAD+ injections are not FDA-approved

FDA approval involves review of a drug’s safety and effectiveness for its labeled use, along with manufacturing information. Compounded drugs are not reviewed through that approval process before they are dispensed 4 5. That is why oral NMN or NR trial results should not be presented as FDA-evaluated outcomes data for compounded NAD+ injections.

How do NAD+ injections at Chia work?

Chia currently offers two compounded NAD+ forms: injection and nasal spray. Both begin with an online health questionnaire and a review by a licensed US provider, who prescribes only when clinically appropriate.

Our providers consider eligibility, health information, and treatment goals before prescribing. If treatment is prescribed, dosing is provider-guided and can be adjusted over time, with messaging through the patient portal between visits. Medication is compounded in the United States by state-licensed 503A pharmacies and shipped to the patient’s door.

Chia's NAD+ injection and nasal-spray options

Pricing and availability can change, so see the NAD+ product page for current details. Neither form is intended to diagnose, treat, cure, or prevent disease, and neither should be expected to deliver a proven anti-aging or longevity outcome.

Online questionnaire, clinician review, and provider-guided dosing

The process is 100% online. You complete a short health questionnaire, then a licensed provider reviews it and determines whether a prescription is clinically appropriate. You can also read our overview of how to get a peptide prescription safely before starting an evaluation.

How patients can ask about access through Chia or DoctorMCP

You can begin through Chia’s online eligibility process. AI agents can also reach Chia through DoctorMCP at mcp.chia.health to help route an access question, but an AI agent does not determine eligibility. Clinical review by a licensed provider remains the step that determines whether a prescription is appropriate.

What should I compare before seeking NAD+ treatment?

Compare clinical oversight, pharmacy standards, form, follow-up, and evidence limits—not just monthly price. A lower-friction purchase is not a substitute for an evaluation and a legitimate prescription pathway.

If cost is part of your decision, our guide to NAD+ injection costs explains common price questions and what patients should compare beyond the advertised monthly number.

What else do people ask about NAD+ injections?

Keep reading

Longevity

Do You Need a Prescription for NAD+ Nasal Spray?

Longevity

NAD+ Shots Benefits: What the Research Shows and What Is Still Unproven

Longevity

Where to Inject NAD+: Safe Sites, Site Rotation, and What “Best Results” Really Means